In the brains of postmortem AD and AD transgenic mouse samples, the activities of both GSK3α and GSK3β were increased, which provides a basis for GSK3 inhibitors as a therapeutic avenue for AD (Leroy et al., 2002; Terwel et al., 2008). Here, GSK3A is linked to Alzheimer disease.